跳至内容 跳至页脚
Trastuzumab-Dttb: Benefits, Reviews, Info, Side Effects!
Rx 详细信息
Trastuzumab-Dttb
Herceptin, Ogivri, Herzuma
Trastuzumab-Dttb
Drug
药物
Biological Product
可用的
Trastuzumab-Dttb is a biosimilar to the drug Herceptin and is used to treat certain types of breast cancer. The benefits of Trastuzumab-Dttb include: 1. Targeted therapy: Trastuzumab-Dttb specifically targets cancer cells that overexpress the HER2 protein, which can help to slow or stop the growth of cancer cells. 2. Improved survival rates: Clinical studies have shown that Trastuzumab-Dttb can improve overall survival rates in patients with HER2-positive breast cancer. 3. Reduced risk of cancer recurrence: Trastuzumab-Dttb can also help to reduce the risk of cancer recurrence in patients who have undergone surgery for HER2-positive breast cancer. 4. Well-tolerated: Trastuzumab-Dttb is generally well-tolerated by patients, with common side effects including nausea, diarrhea, and fatigue. 5. Convenient dosing: Trastuzumab-Dttb is typically administered as an intravenous infusion every 3 weeks, making it a convenient treatment option for patients.
Chills, Cough, Diarrhea, Dizziness, Fatigue, Fever, Headache, Heart Problems, Infections, Infusion-Related Reactions, Low White Blood Cell Count, Nausea, Rash, Shortness Of Breath, Swelling Of The Hands Or Feet, Weakness
Trastuzumab-Dttb, also known as Ontruzant, is a biosimilar to trastuzumab, which is used in the treatment of HER2-positive breast cancer and gastric cancer. The dosage of trastuzumab, including its biosimilars, can vary based on the specific treatment regimen, the type of cancer being treated, and the patient’s body weight or body surface area. For breast cancer, a common initial loading dose is 8 mg/kg, followed by a maintenance dose of 6 mg/kg every three weeks. However, dosing can vary, and it’s important to follow the specific guidance provided by a healthcare professional or the prescribing information for the specific product being used. Always consult with a healthcare provider for the most accurate and personalized dosing information.
Her2-positive breast cancer, her2-positive gastric cancer
Generally well-tolerated with potential for cardiac toxicity.
未报告任何相互作用
$1,000 – $3,000
$1000-$1,500 per vial.

摘要

Trastuzumab-Dttb

Trastuzumab-Dttb is a medication that is commonly used in the treatment of certain types of cancer, specifically HER2-positive breast cancer. This drug is a biosimilar to the original trastuzumab, which means that it has a very similar structure and function to the original medication.

Trastuzumab-Dttb works by targeting and blocking the HER2 protein, which is overexpressed in some types of cancer cells. By blocking this protein, the medication can help to slow down or stop the growth of cancer cells, ultimately leading to a reduction in tumor size and progression of the disease.

It is important to note that trastuzumab-Dttb is typically used in combination with other cancer treatments, such as chemotherapy or radiation therapy, to achieve the best possible outcomes for patients. Your healthcare provider will determine the most appropriate treatment plan for your specific situation.

As with any medication, trastuzumab-Dttb may cause side effects in some patients. Common side effects may include nausea, vomiting, diarrhea, and fatigue. It is important to discuss any concerns or side effects with your healthcare provider, as they may be able to provide guidance or adjust your treatment plan accordingly.

Overall, trastuzumab-Dttb has been shown to be an effective and well-tolerated medication for the treatment of HER2-positive breast cancer. If you have been prescribed this medication, it is important to follow your healthcare provider’s instructions carefully and attend all scheduled appointments to monitor your progress.

RxDb 法律免责声明

RxDB.net 上提供的信息仅供参考,并非旨在取代专业的医疗建议、诊断或治疗。如果您对健康、药物或医疗状况有任何疑问或担忧,请务必咨询合格的医疗保健专业人员,例如医生或药剂师。依赖本网站提供的任何信息的风险完全由您自行承担。RxDB.net 不提供医疗或制药服务,对基于此处包含的信息做出的任何决定概不负责。

页面最后更新时间

0
希望看到您的想法,请您发表评论
zh_CNZH